메뉴 건너뛰기




Volumn 124, Issue 2, 2010, Pages 387-391

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer

Author keywords

Breast cancer; Estrogen receptor; Neoadjuvant chemotherapy; Predictive factors

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; HORMONE RECEPTOR 2; PROGESTERONE; UNCLASSIFIED DRUG;

EID: 78649328099     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1142-2     Document Type: Article
Times cited : (26)

References (23)
  • 1
    • 34547852275 scopus 로고    scopus 로고
    • Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007
    • DOI 10.1093/annonc/mdm271
    • A Goldhirsch WC Wood RD Gelber, et al. 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 1:STN:280:DC%2BD2svlvVSkuw%3D%3D 10.1093/annonc/mdm271 17675394 (Pubitemid 47244357)
    • (2007) Annals of Oncology , vol.18 , Issue.7 , pp. 1133-1144
    • Goldhirsch, A.1    Wood, W.C.2    Gelber, R.D.3    Coates, A.S.4    Thurlimann, B.5    Senn, H.-J.6
  • 2
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • DOI 10.1016/S0140-6736(05)66544-0, PII S0140673605665440
    • Early Breast Cancer Trialists'Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
    • (2005) Lancet , vol.365 , Issue.9472 , pp. 1687-1717
  • 3
    • 34447251650 scopus 로고    scopus 로고
    • Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
    • DOI 10.1200/JCO.2007.11.3290
    • NL Henry DF Hayes 2007 Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? J Clin Oncol 25 2501 2503 1:CAS:528:DC%2BD2sXotV2mt70%3D 10.1200/JCO.2007.11.3290 17577024 (Pubitemid 47041219)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.18 , pp. 2501-2503
    • Henry, N.L.1    Hayes, D.F.2
  • 4
    • 33645729203 scopus 로고    scopus 로고
    • Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    • 1:CAS:528:DC%2BD28XjsVeqs7k%3D 10.1001/jama.295.14.1658 16609087
    • DA Berry C Cirrincione IC Henderson, et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658 1667 1:CAS:528:DC%2BD28XjsVeqs7k%3D 10.1001/jama.295.14. 1658 16609087
    • (2006) JAMA , vol.295 , pp. 1658-1667
    • Berry, D.A.1    Cirrincione, C.2    Henderson, I.C.3
  • 5
    • 24144439984 scopus 로고    scopus 로고
    • ER expression is not bimodal in breast cancer
    • 16196171
    • DC Allred SK Mohsin 2005 ER expression is not bimodal in breast cancer Am J Clin Pathol 124 474 475 16196171
    • (2005) Am J Clin Pathol , vol.124 , pp. 474-475
    • Allred, D.C.1    Mohsin, S.K.2
  • 6
    • 0037125429 scopus 로고    scopus 로고
    • Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial
    • International Breast Cancer Study Group
    • International Breast Cancer Study Group 2002 Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial J Natl Cancer Inst 94 1054 1065
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1054-1065
  • 7
    • 17144369986 scopus 로고    scopus 로고
    • Concurrent versus sequential chemohormonal therapy versus tamoxifen alone for postmenopausal, node-positive, estrogen and/or progesterone receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100
    • Abstract 37
    • Albain K, Barlow W, O'Malley F et al. (2004). Concurrent versus sequential chemohormonal therapy versus tamoxifen alone for postmenopausal, node-positive, estrogen and/or progesterone receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100. Breast Cancer Res Treat 88(suppl 1). Abstract 37
    • (2004) Breast Cancer Res Treat , vol.88 , Issue.SUPPL. 1
    • Albain, K.1    Barlow, W.2    O'Malley, F.3
  • 8
    • 9144242764 scopus 로고    scopus 로고
    • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    • DOI 10.1016/S0959-8049(03)00675-0
    • T Petit M Wilt M Velten, et al. 2004 Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy Eur J Cancer 40 205 211 1:CAS:528:DC%2BD2cXjsVOlsA%3D%3D 10.1016/S0959-8049(03)00675-0 14728934 (Pubitemid 38077022)
    • (2004) European Journal of Cancer , vol.40 , Issue.2 , pp. 205-211
    • Petit, T.1    Wilt, M.2    Velten, M.3    Millon, R.4    Rodier, J.-F.5    Borel, C.6    Mors, R.7    Haegele, P.8    Eber, M.9    Ghnassia, J.-P.10
  • 13
    • 0026072872 scopus 로고
    • Pathological prognostic factors in breast cancer: The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
    • 1:STN:280:DyaK38%2FpvVSltw%3D%3D 10.1111/j.1365-2559.1991.tb00229.x 1757079
    • CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1:STN:280: DyaK38%2FpvVSltw%3D%3D 10.1111/j.1365-2559.1991.tb00229.x 1757079
    • (1991) Histopathology , vol.19 , pp. 403-410
    • Elston, C.W.1    Ellis, I.O.2
  • 14
    • 0031915998 scopus 로고    scopus 로고
    • Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    • 1:STN:280:DyaK1c7mtlaitg%3D%3D
    • DC Allred JM Harvey M Berardo, et al. 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis Modern Pathol 11 155 168 1:STN:280:DyaK1c7mtlaitg%3D%3D
    • (1998) Modern Pathol , vol.11 , pp. 155-168
    • Allred, D.C.1    Harvey, J.M.2    Berardo, M.3
  • 15
    • 67649983962 scopus 로고    scopus 로고
    • Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
    • 1:CAS:528:DC%2BD1MXosVehs7w%3D 10.1200/JCO.2008.18.2808 19380452
    • F Penault-Llorca F André C Sagan, et al. 2009 Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2809 2815 1:CAS:528:DC%2BD1MXosVehs7w%3D 10.1200/JCO.2008.18.2808 19380452
    • (2009) J Clin Oncol , vol.27 , pp. 2809-2815
    • Penault-Llorca, F.1    André, F.2    Sagan, C.3
  • 16
    • 0032190388 scopus 로고    scopus 로고
    • Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance
    • DOI 10.1016/S0959-8049(98)00149-X, PII S095980499800149X
    • DM Barnes RR Millis LV Beex, et al. 1998 Increased use of immunochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance Eur J Cancer 34 1677 1682 1:CAS:528:DyaK1cXntlShtbs%3D 10.1016/S0959-8049(98)00149-X 9893651 (Pubitemid 28474218)
    • (1998) European Journal of Cancer , vol.34 , Issue.11 , pp. 1677-1682
    • Barnes, D.M.1    Millis, R.R.2    Beex, L.V.A.M.3    Thorpe, S.M.4    Leake, R.E.5
  • 18
    • 0034001886 scopus 로고    scopus 로고
    • Testing for erbB-2 by immunohistochemistry in breast cancer
    • 1:CAS:528:DC%2BD3cXhtVWns7o%3D 10.1309/9X6X-1EL6-5QB1-YLD2 10664619
    • DC Allred PE Swanson 2000 Testing for erbB-2 by immunohistochemistry in breast cancer Am J Clin Pathol 113 171 175 1:CAS:528:DC%2BD3cXhtVWns7o%3D 10.1309/9X6X-1EL6-5QB1-YLD2 10664619
    • (2000) Am J Clin Pathol , vol.113 , pp. 171-175
    • Allred, D.C.1    Swanson, P.E.2
  • 19
    • 77954526150 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancers
    • 10.1200/JCO.2009.25.6529 20404251
    • MEH Hammond DF Hayes M Dowsett, et al. 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancers J Clin Oncol 28 2784 2795 10.1200/JCO.2009.25.6529 20404251
    • (2010) J Clin Oncol , vol.28 , pp. 2784-2795
    • Hammond, M.E.H.1    Hayes, D.F.2    Dowsett, M.3
  • 20
    • 75249083420 scopus 로고    scopus 로고
    • Ki67 in breast cancer: Prognostic and predictive potential
    • 1:CAS:528:DC%2BC3cXhtlGgtbc%3D 10.1016/S1470-2045(09)70262-1 20152769
    • R Yerushalmi R Woods PM Ravdin, et al. 2010 Ki67 in breast cancer: prognostic and predictive potential Lancet Oncol 11 174 183 1:CAS:528: DC%2BC3cXhtlGgtbc%3D 10.1016/S1470-2045(09)70262-1 20152769
    • (2010) Lancet Oncol , vol.11 , pp. 174-183
    • Yerushalmi, R.1    Woods, R.2    Ravdin, P.M.3
  • 23
    • 66849140730 scopus 로고    scopus 로고
    • Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    • 1:CAS:528:DC%2BD1MXmtlyit74%3D 10.1093/jnci/djp082 19436038
    • MCU Cheang SK Chia C Voduc, et al. 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736 750 1:CAS:528:DC%2BD1MXmtlyit74%3D 10.1093/jnci/djp082 19436038
    • (2009) J Natl Cancer Inst , vol.101 , pp. 736-750
    • Cheang, M.C.U.1    Chia, S.K.2    Voduc, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.